Anti-IL-27 Antibody

Primary Antibodies

27493 MW

WB: 0.5 - 4 μg/mL; ICC: 10 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in mouse samples. All other applications and species not yet tested. Optimal dilutions for each application should be determined by the researcher.

Interleukin 27

Anti-IL-27 antibody was raised against a peptide corresponding to 16 amino acids near the amino terminus of human IL-27. The immunogen is located within the first 50 amino acids of IL-27.

IL-27 Antibody is affinity chromatography purified via peptide column.

Immunology, Cancer

Associates with EBI3 to form the IL-27 interleukin, a
heterodimeric cytokine which functions in innate immunity. IL-27
has pro- and anti-inflammatory properties, that can regulate T-
helper cell development, suppress T-cell proliferation, stimulate
cytotoxic T-cell activity, induce isotype switching in B-cells,
and that has diverse effects on innate immune cells. Among its
target cells are CD4 T-helper cells which can differentiate in
type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17
producing helper T-cells (TH17). It drives rapid clonal expansion
of naive but not memory CD4 T-cells. It also strongly synergizes
with IL-12 to trigger interferon-gamma/IFN-gamma production of
naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which
appears to be required but not sufficient for IL-27-mediated
signal transduction. IL-27 potentiate the early phase of TH1
response and suppress TH2 and TH17 differentiation. It induces the
differentiation of TH1 cells via two distinct pathways, p38
MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also
induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and
activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-
regulation, an event crucial to TH1 cell commitment. It suppresses
the expression of GATA3, the inhibitor TH1 cells development. In
CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to
be a potent inhibitor of TH17 cell development and of IL-17
production. Indeed IL27 alone is also able to inhibit the
production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed
the development of proinflammatory Th17 cells via STAT1, it
inhibits the development of anti-inflammatory inducible regulatory
T-cells, iTreg, independently of STAT1. IL-27 has also an effect
on cytokine production, it suppresses proinflammatory cytokine
production such as IL2, IL4, IL5 and IL6 and activates suppressors
of cytokine signaling such as SOCS1 and SOCS3. Apart from
suppression of cytokine production, IL-27 also antagonizes the
effects of some cytokines such as IL6 through direct effects on T-
cells. Another important role of IL-27 is its antitumor activity
as well as its antiangiogenic activity with activation of
production of antiangiogenic chemokines such as IP-10/CXCL10 and
MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon
regulatory factor 1 and increase the expression of MHC class II
transactivator/CIITA with resulting up-regulation of major
histocompatibility complex class II. IL-27 also demonstrates
antiviral activity with inhibitory properties on HIV-1
replication.

Boster Bio Anti-IL-27 Antibody (Catalog # A00857-3). Tested in ELISA, WB, ICC applications. This antibody reacts with Human, Mouse.

Rat